Wilmington, NC
PPD, Inc. announced it has entered into an exclusive alliance with DiabetesAmerica, a provider of comprehensive diabetes care services based in Houston, Texas. Under the agreement, PPD will provide clinical research training and support to more than 20 clinical trial investigators who will conduct Type 1 and Type 2 diabetes clinical trials from DiabetesAmerica's 17 centers across Texas and Arizona.
In return, DiabetesAmerica will work exclusively with PPD to provide clinical research services for endocrine and metabolic disease development programs over a minimum of three years. The agreement expands PPD's ability to recruit for diabetes-related clinical trials through the use of DiabetesAmerica's 16,000-plus patient database.
"Diabetes is a disease with serious complications that affects more than 23 million Americans," said Mike Wilkinson, executive vice president of clinical development at PPD. "We are pleased to assist these physicians in bringing cutting-edge diabetes treatments to their patients through training and support. In addition, DiabetesAmerica's patient database expands our ability to offer clinical trial options to a broader population of people living with this increasingly common disease."
"DiabetesAmerica is committed to delivering the latest treatments in diabetes care to our patients," said Rosemary Mazanet, MD, PhD, and CEO of DiabetesAmerica. "Our alliance with PPD will help ensure our physicians are fully trained on managing drug development programs so we can continue to bring complete diabetes care to our patients."
See a free diabetes and obesity podcast series to learn more about clinical trials in these therapeutic areas.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.